Patents Issued in December 5, 2019
  • Publication number: 20190365816
    Abstract: This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.
    Type: Application
    Filed: August 15, 2019
    Publication date: December 5, 2019
    Inventors: Tien Lee, Hans G. Klingemann, Barry J. Simon, Laurent Boissel
  • Publication number: 20190365817
    Abstract: A platform for ex vivo isolation, production, and formulation of genetically-modified cells is described. The platform utilizes a software-enabled point-of-care and/or portable device making gene therapy more widely available.
    Type: Application
    Filed: May 24, 2019
    Publication date: December 5, 2019
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Jennifer E. Adair, Hans-Peter Kiem
  • Publication number: 20190365818
    Abstract: The present invention provides stably tagged stem cells and methods for producing stem cells comprising one or more tagged proteins using a gene editing system. The methods described herein enable the insertion of large fluorescent tags into a plurality of genomic loci to generate stem cells that are phenotypically and functional similar to the un-modified parent population. Stem cells produced by the methods described herein additionally retain the capacity to self-renew and differentiate into specialized cell types and can be used in assays and visualization of three-dimensional live cell imaging.
    Type: Application
    Filed: February 9, 2018
    Publication date: December 5, 2019
    Inventors: Ruwanthi GUNAWARDANE, Brock ROBERTS, Amanda HAUPT, Andrew TUCKER
  • Publication number: 20190365819
    Abstract: A composition for influencing biological growth including live cells, a fluid comprising dextrose, a protectant, and a first cytokine having a first concentration within the composition as described within the present disclosure.
    Type: Application
    Filed: August 19, 2019
    Publication date: December 5, 2019
    Inventors: Christopher D. Jones, Soumyajit Banerjee Mustafi
  • Publication number: 20190365820
    Abstract: The present invention relates to a complex for promoting cartilage differentiation comprising stem cells or a culture thereof and a cartilage cell-free crush, a method for fabricating cartilage by using the complex, cartilage fabricated via the method, a pharmaceutical composition comprising the complex for preventing or treating arthropathy, a method for preventing or treating arthropathy using the composition, a composition for inducing cartilage cell differentiation comprising the prepared cartilage cells, and a method for fabricating cartilage using the prepared cartilage cells.
    Type: Application
    Filed: July 4, 2017
    Publication date: December 5, 2019
    Inventors: Kyung Sun Kang, Kwang Won Seo, Kyung Ae Yoon, Hyo Jin Jeon, Yun Beom Sim
  • Publication number: 20190365821
    Abstract: An in vitro method of producing a population of muscle stem cells comprising co-culturing pluripotent stem cells, embryonic fibroblast cells and endothelial cells in 3D cell culture.
    Type: Application
    Filed: November 3, 2017
    Publication date: December 5, 2019
    Inventors: Omid Mashinchian, Jerome Feige, Conrad Florian Bentzinger
  • Publication number: 20190365822
    Abstract: Disclosed herein are compositions comprising cardiac progenitor cells that express exogenous p53 protein. Such compositions are useful for treating cardiac diseases or disorders. Also disclosed herein are methods of producing cardiac progenitor cells that express exogenous p53.
    Type: Application
    Filed: February 1, 2018
    Publication date: December 5, 2019
    Applicant: AAL SCIENTIFICS, INC.
    Inventors: Piero ANVERSA, Annarosa LERI
  • Publication number: 20190365823
    Abstract: Cell populations of intestinal midgut endoderm cells and methods of generating the cells expressing markers characteristic of intestinal endoderm lineage are disclosed. Methods of treating conditions such as diabetes are also disclosed.
    Type: Application
    Filed: August 14, 2019
    Publication date: December 5, 2019
    Applicant: Janssen Biotech, Inc.
    Inventors: Sebastian Rieck, Alireza Rezania
  • Publication number: 20190365824
    Abstract: The present invention relates to the use of eggshell membrane compositions to activate levels of nuclear factor kappa-light-chain-enhancer of activated B cells (“NF-?B”) in the gut of a host in need thereof and methods of treating conditions related to NF-?B dysregulation.
    Type: Application
    Filed: June 6, 2019
    Publication date: December 5, 2019
    Inventor: KEVIN J. RUFF
  • Publication number: 20190365825
    Abstract: Provided are: a method for producing a nasal drop composition suitable for treatment or prevention of a disease or symptom in the nasal cavities; and a nasal drop composition produced by the production method. The nasal drop composition production method characterized by including a mixing step of mixing earthworm castings with water and a collecting step of collecting vaporized water generated from a mixture obtained in the mixing step to obtain a liquid; and the nasal drop composition produced by the production method. It is preferred to further mix an organic substance together with the earthworm castings and the water in the mixing step.
    Type: Application
    Filed: March 16, 2018
    Publication date: December 5, 2019
    Applicant: WELL STONE CO.
    Inventors: Yoichi ISHII, Takeshi OKAMOTO, Sayaka MAKINO
  • Publication number: 20190365826
    Abstract: An object of the present invention is to provide: a Tau protein production accelerator containing a natural product as an active ingredient; a therapeutic or preventive agent for a disease caused by Tau protein deficiency; and a therapeutic or preventive food composition for a disease caused by Tau protein deficiency. Provided are: a Tau protein production accelerator containing a dry powder ground product and/or extract of an earthworm as an active ingredient; a therapeutic or preventive agent for a disease caused by Tau protein deficiency; and a therapeutic or preventive food composition for a disease caused by Tau protein deficiency. The disease caused by Tau protein deficiency is preferably Alzheimer's disease.
    Type: Application
    Filed: July 17, 2019
    Publication date: December 5, 2019
    Applicant: WELL STONE CO.
    Inventors: Yoichi ISHII, Takayuki NEMOTO, Takeshi OKAMOTO
  • Publication number: 20190365827
    Abstract: Provided is a composition for treating a diabetic disease, which serves as a meal substitution for a patient having the diabetic disease. The composition contains a vegetable powder mixture and/or cricket powders.
    Type: Application
    Filed: July 17, 2018
    Publication date: December 5, 2019
    Inventor: Sam Goo LEE
  • Publication number: 20190365828
    Abstract: The present invention provides a fermented product obtained by fermenting honey and camomile or a treated product thereof with Lactobacillus kunkeei.
    Type: Application
    Filed: December 21, 2017
    Publication date: December 5, 2019
    Inventors: Asami HAGA, Madoka ISOE, Ayanori YAMAKI, Yuka KIMURA
  • Publication number: 20190365829
    Abstract: The ubiquitin ligase, RNF5, regulates the gut microbiota composition and influences the immune checkpoint response to tumors. RNF5 deficient animals exhibit significant inhibition of tumor development as well as an altered gut microbiota composition. Methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species are disclosed. Also disclosed are methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species in combination with one or more anti-cancer agents.
    Type: Application
    Filed: November 17, 2017
    Publication date: December 5, 2019
    Inventors: Yan Li, Scott Peterson, Linda Bradley, Roberto Tinoco, Ze`ev Ronai, Shiri Ashkenazi
  • Publication number: 20190365830
    Abstract: Provided herein are methods of treating cancer and/or augmenting a microbiome in a subject who has a tumor.
    Type: Application
    Filed: January 18, 2018
    Publication date: December 5, 2019
    Inventors: Brian Goodman, Leslie Wardwell-Scott, Alexandra Sirota-Madi, Erin B. Troy, Samuel W. Andrewes
  • Publication number: 20190365831
    Abstract: Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag.
    Type: Application
    Filed: August 19, 2019
    Publication date: December 5, 2019
    Applicant: REBIOTIX, INC.
    Inventors: Lee A. Jones, Courtney R. Jones, Beth Anne-Szkudlarek Brown, Joshua Erickson
  • Publication number: 20190365832
    Abstract: The present invention provides a method of treating a disease or condition characterized by inflammation in a subject in need thereof, comprising administering to the subject an effective amount of a Pediococcus acidilactici probiotic. Compositions of Pediococcus acidilactici probiotic are also provided.
    Type: Application
    Filed: February 4, 2019
    Publication date: December 5, 2019
    Inventors: Jhy-Jhu Lin, Jolinta Lin
  • Publication number: 20190365833
    Abstract: The present invention relates to certain microorganisms or mixtures thereof for use in the treatment and/or prevention of inflammation in the oral cavity, preferably for the treatment and/or prevention of gingivitis and/or peridontitis. In particular, the present invention relates to microorganisms or mixtures thereof for use as probiotic agents for forming co-aggregates with microorganisms associated with gingivitis and/or peridontitis. Furthermore, the present invention provides oral pharmaceutical compositions, oral care products or products for nutrition or pleasure comprising one or more of the probiotic microorganisms as active agents as well as a method of production thereof.
    Type: Application
    Filed: January 17, 2018
    Publication date: December 5, 2019
    Inventors: Marcus Rudolf GÖTZ, Kerstin HOLMGREN, Niklas LARSSON, Bernd FIEBICH, William WADE
  • Publication number: 20190365834
    Abstract: The subject matter of the instant invention relates to methods of compounding compositions comprising bacteriophage effective for treating bacterial infections, including but not limited to, multidrug resistant bacterial infections. The invention also relates to compositions, bacterial diversity sets, and phage libraries prepared according to the methods of the instant invention.
    Type: Application
    Filed: June 7, 2019
    Publication date: December 5, 2019
    Applicant: United States of America as Represented by the Secretary of the Navy
    Inventors: James M. Regeimbal, Biswajit Biswas, Matthew S. Henry
  • Publication number: 20190365835
    Abstract: Provided herein are methods of producing an adeno-associated virus (AAV) product, methods of purifying adeno-associated virus, and methods of purifying full AAV capsids from a concentrated AAV fraction comprising empty AAV capsids and full AAV capsids.
    Type: Application
    Filed: November 3, 2017
    Publication date: December 5, 2019
    Applicants: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Christian FIEDLER, Leopold GRILLBERGER, Meinhard HASSLACHER, Barbara KRAUS, Dominik MITTERGRADNEGGER, Stefan REUBERGER, Horst SCHAFHAUSER, Marian BENDIK
  • Publication number: 20190365836
    Abstract: This document provides methods and materials involved in treating cancer. For example, methods and materials for using an inhibitor of UFM1 activity or expression and/or an inhibitor of UFL1 activity or expression to reduce a cancer cell's ability to carry out a DDR, thereby increasing the sensitivity of cancer cells to treatment with a DNA damaging therapy such as radiation or chemotherapy, are provided.
    Type: Application
    Filed: January 11, 2018
    Publication date: December 5, 2019
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Evanthia GALANIS, S. Keith ANDERSON, Cheyne B. KUROKAWA, Ianko D. IANKOV
  • Publication number: 20190365837
    Abstract: This anti-NASH composition, this food composition for preventing NASH, and this beverage composition for preventing NASH include, as an active ingredient, a Basidiomycetes-X FERM BP-10011 dry powder or an extract composition thereof. In addition, a composition for preventing cirrhosis and a composition for preventing hepatocellular carcinoma include, as an active ingredient, a Basidiomycetes-X FERM BP-10011 dry powder or an extract composition thereof, and prevent metastasis of cirrhosis and hepatocellular carcinoma from NASH.
    Type: Application
    Filed: February 6, 2018
    Publication date: December 5, 2019
    Inventors: Kenichi WATANABE, Tetsuya KONISHI, Yusuke KOGA
  • Publication number: 20190365838
    Abstract: Provided are a method of efficiently producing a ginseng leaf extract including rare ginsenosides Rg6, Rk3, and Rh4 in increased amounts, and use of a ginseng leaf extract produced by the method.
    Type: Application
    Filed: May 31, 2019
    Publication date: December 5, 2019
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Jungyeob HAM, Taejung KIM, Young Tae PARK, Kyusun KIM, Pilju CHOI, Seon-Jun CHOI, Bong Geun SONG, Jae Young CHOI
  • Publication number: 20190365839
    Abstract: The invention discloses synergistic compositions comprising at least one component selected from extract(s) and fraction(s) or mixtures thereof derived from Sphaeranthus indicus in combination with at least one component selected from extract(s), fraction(s), active compound(s) or mixtures thereof derived from Terminalia chebula for improving the liver health. The invention further discloses method of improving the liver health in humans and animals by administering the compositions comprising at least one component selected from extract(s) and fraction(s) or mixtures thereof derived from Sphaeranthus indicus in combination with at least one component selected from extract(s), fraction(s), active compound(s) or mixtures thereof derived from Terminalia chebula.
    Type: Application
    Filed: November 20, 2017
    Publication date: December 5, 2019
    Inventors: Ganga Raju GOKARAJU, Rama Raju GOKARAJU, Venkata Kanaka Ranga Raju GOKARAJU, Trimurtulu GOLAKOTI, Kiran BHUPATHIRAJU, Venkata Krishna Raju ALLURI
  • Publication number: 20190365840
    Abstract: The present invention discloses a cancer treatment method which includes the step of treating a patient having cancer with an extract from Galenia africana L. plant. The extract may include pinocembrin and/or 2?,4? dihydroxychalcone and/or 7-hydroxyflavanone. The cancer may be breast cancer or melanoma. The composition may be solubilized with MPG and/or Suganate.
    Type: Application
    Filed: December 19, 2017
    Publication date: December 5, 2019
    Inventor: Michael-John Joseph BARRY
  • Publication number: 20190365841
    Abstract: The present disclosure relates to the field of healthcare foods. Disclosed is a composition having functions of improving kidney yang, enhancing immunity and relieving fatigue, which is an aqueous extract of ASTRAGALI RADIX, REHMANNIAE RADIX, EUCOMMIAE CORTEX, MORINDAE OFFICINALIS RADIX, LYCII FRUCTUS and POLYGONATI RHIZOMA. By using six traditional Chinese herb medicines, ASTRAGALI RADIX, REHMANNIAE RADIX, EUCOMMIAE CORTEX, MORINDAE OFFICINALIS RADIX, LYCII FRUCTUS and POLYGONATI RHIZOMA for decoction extraction, a composition having functions of improving kidney yang, enhancing immunity and relieving fatigue is obtained. Through synergetic function of each traditional Chinese herb medicine, the composition achieves a better effect comparing with similar products. In addition, the species of traditional Chinese medicine in the composition is relatively fewer, lowering the potential safety hazard, and the method is simple and the cost is low.
    Type: Application
    Filed: December 30, 2018
    Publication date: December 5, 2019
    Applicant: INFINITUS (CHINA) COMPANY LTD.
    Inventors: Shuo LIU, Wenzhi LI, Siyao MA
  • Publication number: 20190365842
    Abstract: Compositions for improving erectile function or treating erectile dysfunction include active ingredients of Muira Puama extract, Quercetin, Chlorophytum Borivilianum (Safed Musli), Dimethylethanolamine (DMAE), niacin, Tribulus Terrestris extract, alpha-lipoic acid, Horny Goat Weed (Epimedium grandfiflorum), Panax ginseng, and saw palmetto berry extract, and may also include magnesium aspartate, Zinc oxide, and Maca root (Lepidium meyenii). Additional active ingredients include Avena Sativa extract (oat straw), L-Taurine, L-Lysine hydrochloride (HCl), a L-Arginine, and/or L-Carnitine.
    Type: Application
    Filed: January 3, 2019
    Publication date: December 5, 2019
    Inventors: Yong Wu, Ke Wu, Gordon Lee, Wei Cao, Huabing Yang
  • Publication number: 20190365843
    Abstract: Disclosed are the antimicrobial effects of bioactive compounds isolated from Curcuma species and their derivatives. Specifically, the invention discloses the growth inhibition of and management of infections caused by Enteroaggregative Escherichia coli (EAEC), Enterotoxigenic Escherichia coli (ETEC) and Pleisiomonas species by curcuminoids, calebin A and their derivatives.
    Type: Application
    Filed: May 29, 2018
    Publication date: December 5, 2019
    Inventors: Anju Majeed, Muhammed Majeed, Kalyanam Nagabhushanam, Nooruddin Thajuddin, Sivakumar Arumugam, Krishnamurthy Kulithalai Viswanathan, Samuel Thomas Manoharan, Furqan Ali, John Adams Sebastian
  • Publication number: 20190365844
    Abstract: This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain aspects the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.
    Type: Application
    Filed: April 22, 2019
    Publication date: December 5, 2019
    Inventors: Ravindra Kumar, Jonathan Belk, Asya Grinberg, Dianne Sako, Roselyne Castonguay
  • Publication number: 20190365845
    Abstract: The invention provides methods of treating an obstructive coronary artery disease in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof and performing a coronary artery bypass graft procedure on the subject.
    Type: Application
    Filed: October 23, 2018
    Publication date: December 5, 2019
    Inventors: Kenneth Borow, D. Travis Wilson
  • Publication number: 20190365846
    Abstract: The disclosure generally describes methods of preventing or treating Lebers hereditary optic neuropathy (LHON). The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.
    Type: Application
    Filed: November 2, 2018
    Publication date: December 5, 2019
    Applicant: Stealth BioTherapeutics Corp
    Inventor: D. Travis Wilson
  • Publication number: 20190365847
    Abstract: This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active octreotide at a constant rate for an extended period of time and methods of manufactures thereof. The device is very bio-compatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of octreotide to tissues car organs.
    Type: Application
    Filed: June 28, 2019
    Publication date: December 5, 2019
    Applicant: Endo Pharmaceuticals Solutions Inc.
    Inventors: Petr Kuzma, Harry Quandt
  • Publication number: 20190365848
    Abstract: A method for treating ascites patients by administering the peptide drug terlipressin by continuous infusion. The patients include those whose ascites condition has not progressed to hepatorenal syndrome (HRS). Administration may be accomplished with a continuous infusion pump.
    Type: Application
    Filed: April 9, 2019
    Publication date: December 5, 2019
    Inventors: Paolo Angeli, Penelope Markham, Jonathan Adams
  • Publication number: 20190365849
    Abstract: Absorbent structures for absorbent articles are provided. The absorbent structure includes an absorbent layer with absorbent material supported by a supporting sheet, and a channel that is free of said absorbent material. The channel has a wet integrity of at least 20%.
    Type: Application
    Filed: August 15, 2019
    Publication date: December 5, 2019
    Inventors: Rodrigo ROSATI, Carsten Heinrich KREUZER, Hans Adolf JACKELS, Blanca ARIZTI, Ernesto G BIANCHI, Donald Carroll ROE
  • Publication number: 20190365850
    Abstract: The present invention is directed to antimicrobial agents and compositions including the same. The antimicrobial agent can include a polypeptide or a peptidomimetic of the polypeptide. The polypeptide can have a net positive charge of at least about 3 at a pH of 7.0, and a hydrophobicity of greater than 25%.
    Type: Application
    Filed: February 16, 2018
    Publication date: December 5, 2019
    Inventors: Shuping Zhang, Ming Yang
  • Publication number: 20190365851
    Abstract: SDC2, compositions that comprise SDC2, vectors encoding SDC2 and compounds that modulate expression of SDC2 by cells are used for treatment of mammalian, e.g. human, cells to achieve immunomodulation or for other specific therapeutic interventions. Cells are treated by combining the cells with SDC2, treating the cells with an antibody or fragment thereof that binds SDC2 or modulating expression or activity of SDC2 by the cells. Cells or tissue are derived from treated cells for therapeutic uses based on their immunomodulatory or other therapeutic properties.
    Type: Application
    Filed: January 22, 2019
    Publication date: December 5, 2019
    Inventor: Stephen Joseph Elliman
  • Publication number: 20190365852
    Abstract: Disclosed herein are recombinant baculoviruses suitable for introducing an exogenous gene into a pest insect, particularly, disease-transmitting mosquitos. The recombinant baculovirus is characterized in having a promotor that is any of a HzNV-1 viral early expressing gene pag1, a ceropin gene b1, a defensin gene a4, or hp70 gene; and an exogenous gene operably linked thereto the promoter. Also disclosed herein is a method of introducing an exogenous gene into a pest insect. The method includes transducing the pest insect with a recombinant baculovirus without suppressing the production of microRNAs (miRNAs) in the pest insect, wherein the recombinant baculovirus comprises a promoter of pag1, cecropin b1, defensin gene a, or hp70.
    Type: Application
    Filed: May 30, 2018
    Publication date: December 5, 2019
    Applicants: Academia Sinica, Chung Yuan Christian University, National Defense Medical Center
    Inventors: Yu-Chan CHAO, Nenavath Gopal NAIK, Tzong-Yuan WU, Chang-Chi LIN, Szu-Cheng KUO
  • Publication number: 20190365853
    Abstract: Provided herein are methods and compositions useful for human health, e.g., for targeting one or more microorganisms resident in a host insect (e.g., arthropod, e.g., insect, e.g., pathogen vector), the modulation resulting in a decrease in the fitness of the host. The invention features a composition that includes a modulating agent (e.g., phage, peptide, small molecule, antibiotic, or combinations thereof) that can alter the host's microbiota in a manner that is detrimental to the host. By disrupting microbial levels, microbial activity, microbial metabolism, or microbial diversity, the modulating agent described herein may be used to decrease the fitness of a variety of insects that carry vector-borne pathogens that cause disease in humans.
    Type: Application
    Filed: January 24, 2018
    Publication date: December 5, 2019
    Inventors: Ignacio MARTINEZ, Zachary Garo ARMEN, Christine CEZAR, Barry Andrew MARTIN, Maier Steve AVENDANO AMADO
  • Publication number: 20190365854
    Abstract: Compositions containing apoaequorin and vitamin D and methods for their use in treating symptoms and disorders related to calcium imbalances and vitamin D deficiency associated with, for example, sleep quality, energy quality, mood quality, memory quality or pain are provided by the present invention
    Type: Application
    Filed: September 25, 2017
    Publication date: December 5, 2019
    Inventor: Mark Y. Underwood
  • Publication number: 20190365855
    Abstract: A method for classifying patients at risk for cardiovascular disease, other chronic inflammatory diseases, cardiovascular and/or non-cardiovascular morbidity and mortality based on a risk assessment for lymphocyte activation gene 3 (LAG3) protein deficiency, and for mediating the risk using recombinant lymphocyte activation gene-3 or LAG-3 mimetic as a companion therapeutic alone or in combination with a statin and/or an anti-hyperlipidemic drug. The risk assessment is two-prong, beginning with a qualitative determination whether a subject has or is predisposed to abnormal expression of inflammasomes, heightened risk for inflammation and/or to dysfunctional HDL, followed by a quantitative assay or genetic screen for a polymorphism that occurs in the coding sequence of the LAG3 gene. Given positive indication, recombinant LAG3 and/or LAG3 mimetic is used alone or in combination with the therapeutic use of a cholesterol mediating drug for treatment.
    Type: Application
    Filed: March 21, 2019
    Publication date: December 5, 2019
    Inventor: Annabelle Rodriguez Oquendo
  • Publication number: 20190365856
    Abstract: The present invention is based on the seminal concept of treating pain by promoting neuronal differentiation. The invention provides a screening method for the selection of agents for the purpose of treating pain, utilizing neuronal differentiation as selection criteria. Methods and libraries available for screening for the selection of candidate agents are provided.
    Type: Application
    Filed: August 16, 2019
    Publication date: December 5, 2019
    Inventor: Gabriel Rusanescu
  • Publication number: 20190365857
    Abstract: The technology described herein is directed to methods and compositions for the treatment of hypertension, e.g. pulmonary arterial hypertension, relating to inhibition of TGF?1, TGF?3, and/or GDF-15.
    Type: Application
    Filed: January 29, 2019
    Publication date: December 5, 2019
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Lai-Ming Yung, Paul B. Yu
  • Publication number: 20190365858
    Abstract: The disclosure relates to methods and compositions for rejuvenating neuromuscular junctions, and treating, preventing, or delaying the onset of, neuromuscular junction fragmentation and related disorders, neuromuscular junction degeneration and related disorders, motor neuron degeneration and related disorders, skeletal muscle conditions (e.g., muscle atrophy), and neuromuscular diseases (e.g., amyotrophic lateral sclerosis).
    Type: Application
    Filed: June 14, 2019
    Publication date: December 5, 2019
    Inventor: Amy J. Wagers
  • Publication number: 20190365859
    Abstract: The present invention provides a preventive or therapeutic agent for an inflammatory skin disease, such as psoriasis, the agent comprising an oligopeptide as an active ingredient. More specifically, the invention provides a preventive or therapeutic agent for an inflammatory skin disease, the agent comprising an oligopeptide consisting of an amino acid sequence containing a DE loop sequence of RANKL protein and a ?-strand D sequence of RANKL protein placed adjacent to the N-terminal side of the DE loop sequence.
    Type: Application
    Filed: November 7, 2017
    Publication date: December 5, 2019
    Inventors: Munehisa Shimamura, Hironori Nakagami, Yuka Ikeda, Ryuichi Morishita, Hiroshi Koriyama
  • Publication number: 20190365860
    Abstract: A method of treating a sphincter deficiency disorder (e.g., incontinence; gastrointestinal disorders) is carried out by administering stromal cell-derived factor 1 (SDF-1) to a sphincter or sphincter complex, such as a urethral or gastrointestinal sphincter (e.g., a rectal sphincter) of the subject in a treatment-effective amount.
    Type: Application
    Filed: August 15, 2019
    Publication date: December 5, 2019
    Inventor: James K. Williams
  • Publication number: 20190365861
    Abstract: The present invention is directed to novel IL-15/IL-15R? heterodimeric Fc fusion proteins and uses thereof. The IL-15/IL-15R? heterodimeric Fc fusion proteins can be administered to a patient to treat cancer. In some cases, the IL-15/IL-15R? heterodimeric Fc fusion protein is administered in combination with a checkpoint blockage antibody such as a PD-1 antibody.
    Type: Application
    Filed: April 18, 2019
    Publication date: December 5, 2019
    Inventors: Matthew Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
  • Publication number: 20190365862
    Abstract: Compositions that specifically cleave target sequences in Flavivirus, for example Zika virus include a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) associated endonuclease, a guide RNA sequence complementary to a target sequence in a Zika virus and an anti-viral agent. These compositions are administered to a subject for treating an infection or at risk for contracting a Zika virus infection.
    Type: Application
    Filed: October 12, 2017
    Publication date: December 5, 2019
    Inventors: Kamel Khalili, Ilker K. Sariyer, Hassen Wollebo
  • Publication number: 20190365863
    Abstract: This document relates to methods and materials for treating functional dyspepsia. For example, methods and materials for using secretin to treat functional dyspepsia are provided.
    Type: Application
    Filed: December 20, 2017
    Publication date: December 5, 2019
    Applicant: Mayo Foundation for Medical Education and Research
    Inventor: Laurence J. Miller
  • Publication number: 20190365864
    Abstract: The present invention refers to lixisenatide for use in pediatrics.
    Type: Application
    Filed: February 4, 2019
    Publication date: December 5, 2019
    Inventors: Karin Bergmann, Agnes Hincelin-Mery, Christelle Jan
  • Publication number: 20190365865
    Abstract: A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.
    Type: Application
    Filed: August 19, 2019
    Publication date: December 5, 2019
    Inventors: Bjarne DUE LARSEN, Jonathan GRIFFIN, Lise GIEHM, Alistair Vincent Gordon EDWARDS